Prognostic values of molecular subtypes and SWI/SNF protein expression in de‐differentiated/undifferentiated endometrial carcinoma
Histopathology · 2025
DOI: 10.1111/his.15411 ↗At a glance
Journal article in Histopathology, 2025. Written by Chae Young Shin and 15 co-authors. Institution: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Major MEDLINE topics: Endometrial Neoplasms, Transcription Factors, Biomarkers, Tumor, Chromosomal Proteins, Non-Histone. Cited 8 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Faculty of Medicine, University of British Columbia, CIHR, Terry Fox Research Institute.
Abstract (original language)
Aims
Classification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant ( POLE mut) with almost no recurrence or disease‐specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes. However, the applicability of molecular classification is unclear in rare but aggressive histotypes of EC, e.g. de‐differentiated and undifferentiated endometrial cancers (DD/UDEC). Here, we aim to assembled a cohort of DD/UDEC from a single institution and analysed the prognostic significance of ProMisE molecular subtypes and the expression of SWItch/sucrose non‐fermentable (SWI/SNF) chromatin remodelling complex members, previously implicated in the pathogenesis of DD/UDEC. Methods and results We accrued 88 DD/UDEC cases, assessed POLE status by Sanger sequencing and performed immunohistochemistry for p53, mismatch repair and SWI/SNF proteins on the tissue microarrays assembled. Assignment of molecular subtypes was possible in 80 tumours; POLE sequencing failed in the remaining eight cases. There were 12 (15%) POLE mut, 44 (55%) MMRd, 14 (17.5%) p53abn and 10 (12.5%) NSMP DD/UDEC. POLE mut DD/UDECs had excellent outcomes, but the other three molecular subtypes all had poor outcomes, with no significant differences among them. The loss of one or more SWI/SNF proteins [AT‐rich interactive domain‐containing protein 1A (ARID1A), ARID1B, SWI/SNF‐related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), SMARCA2], observed in 66% (55 of 83) cases, was not of prognostic significance.
Conclusions
These results indicate that all molecular subtypes of DD/UDEC except POLE mut behave in an aggressive fashion. Further study is needed to determine whether these molecular alterations can be targeted with adjuvant therapy, in order to improve outcomes of patients with DD/UDEC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Ovarian Cancer Research Centre, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.
- Department of Molecular Oncology, British Columbia Cancer Research Institute, Vancouver, British Columbia, Canada.
- Department of Pathology, McGill University, Montreal, Quebec, Canada.
- Genetic Pathology Evaluation Center, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology, University of British Columbia and BC Cancer, Vancouver, British Columbia, Canada.
ORCID profiles: Bengul Gokbayrak, Felix Kf Kommoss, Jutta Huvila, Derek Chiu, Samuel Leung, Basile Tessier-Cloutier, David G Huntsman, C Blake Gilks, Jessica N McAlpine, Lynn Hoang, Yemin Wang
Funding
- Faculty of Medicine, University of British Columbia
- CIHR
- Terry Fox Research Institute
- Canadian Institutes of Health Research
Cite
APA
Shin, C. Y., Gokbayrak, B., Tao, V. L., Almadani, N., S Li, E., Ho, R., Kommoss, F. K., Huvila, J., Chiu, D., Leung, S., Tessier-Cloutier, B., Huntsman, D. G., Gilks, C. B., McAlpine, J. N., Hoang, L., & Wang, Y. (2025). Prognostic values of molecular subtypes and SWI/SNF protein expression in de‐differentiated/undifferentiated endometrial carcinoma. Histopathology. https://doi.org/10.1111/his.15411
Vancouver
Shin CY, Gokbayrak B, Tao VL, Almadani N, S Li E, Ho R, et al. Prognostic values of molecular subtypes and SWI/SNF protein expression in de‐differentiated/undifferentiated endometrial carcinoma. Histopathology. 2025. doi:10.1111/his.15411
BibTeX
@article{Shin2025,
author = {Shin, Chae Young and Gokbayrak, Bengul and Tao, Valerie L and Almadani, Noorah and S Li, Eunice and Ho, Rebecca and Kommoss, Felix Kf and Huvila, Jutta and Chiu, Derek and Leung, Samuel and Tessier-Cloutier, Basile and Huntsman, David G and Gilks, C Blake and McAlpine, Jessica N and Hoang, Lynn and Wang, Yemin},
title = {Prognostic values of molecular subtypes and SWI/SNF protein expression in de‐differentiated/undifferentiated endometrial carcinoma},
journal = {Histopathology},
year = {2025},
doi = {10.1111/his.15411}
}
EUVIMED